Given that the activation of EGFR signalling tends overall to inhibit autophagy (Figure 4B,D), gefitinib and erlotinib inhibition of EGFR signalling was unsurprisingly found to induce autophagy in a dose-dependent manner and in multiple cancer cells of multiple origins [143] (Figure 4E,H)). The gene discussed is EGFR; the disease is cancer.